Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

GEM-132 enters phase I safety and pharmacokinetic trial

Aug. 23, 1996

SmithKline Beecham describes protease inhibitors

Aug. 23, 1996

Isis now fully owns fomivirsen

Aug. 23, 1996

Solvay to copromote Famvir in U.S.

Aug. 23, 1996

Sequus and Torrex Pharma sign Amphotec marketing agreement

Aug. 23, 1996

Xoma granted permission to commence phase III for rBPI21

Aug. 23, 1996

Parke-Davis and Xenova begin evaluation of novel antibacterial

Aug. 23, 1996

Takeda describes cephem antibacterial agents

Aug. 23, 1996

HHV-8 implicated in KS development

Aug. 16, 1996

Lidak initiates further trials of Lidakol in oral herpes

Aug. 16, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...